Clinical Trials

We are aiming to start a Phase 1 study of our lead Treg cell therapy candidate in patients with rheumatoid arthritis as soon as possible.

We are currently conducting a Phase 1 study of SBT-11-5301, our effector T cell-modulating biologic, in healthy participants.

For more information on the Phase 1 study of SBT-11-5301 in healthy participants, please visit